← Leaderboards
Ellen S Vitetta
University Of Texas Sw Med Ctr/Dallas
$11,813,406
Attributed
$11,813,406
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$10,872,135 · 8
FDA$941,271 · 1
By mechanism
U01$5,865,385 · 2
R01$4,497,475 · 5
RC2$1,303,720 · 1
P51$146,826 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Immunoconjugates”
- Edward A Neuwelt · Oregon Health And Science University$8,971,593
- Rakesh K. Jain · Massachusetts General Hospital$8,290,808
- Kim D Janda · Scripps Research Institute$8,002,711
- Brian Matthew Zeglis · Sloan-Kettering Inst Can Research$4,383,787
- Darell D Bigner · Duke University$4,368,080
- Bogdan Olenyuk · California Institute Of Technology$3,812,988
Research focus
ImmunoconjugatesRicinScid MouseImmunotoxicityTissue /Cell CultureLaboratory MouseRecombinant ProteinsNeoplasm /Cancer ChemotherapyAmino AcidsImmunoglobulin GKillingsVaccinationStructureAntibody FormationAntibodiesBaseActive ImmunizationEscherichia ColiAerosolsReportingGrantVaccinatedImmunogenicVaccines
Grant awards (32)
Development of a lyophilized intradermal/intranasal ricin vaccine$735,115
U01 · FY2010 · AI · contact PI
A novel vaccine to prevent HCV infection and hence liver cancer$620,020
RC2 · FY2010 · CA · contact PI
A novel vaccine to prevent HCV infection and hence liver cancer$683,700
RC2 · FY2009 · CA · contact PI
Development of a lyophilized intradermal/intranasal ricin vaccine$540,262
U01 · FY2009 · AI · contact PI
PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN$311,884
R01 · FY2009 · FD · contact PI
Development of a lyophilized intradermal/intranasal ricin vaccine$615,696
U01 · FY2008 · AI · contact PI
PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN$321,672
R01 · FY2008 · FD · contact PI
Development of a lyophilized intradermal/intranasal ricin vaccine$588,276
U01 · FY2007 · AI · contact PI
PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN$307,715
R01 · FY2007 · FD · contact PI
Development of a lyophilized intradermal/intranasal ricin vaccine$764,532
U01 · FY2006 · AI · contact PI
A Novel Recombinant Protein Vaccine Against Ricin Toxin$604,986
U01 · FY2006 · AI · contact PI
The reversal of multidrug resistance by an anti-CD19 ab.$239,926
R01 · FY2006 · CA · contact PI
A Novel Recombinant Protein Vaccine Against Ricin Toxin$678,824
U01 · FY2005 · AI
The reversal of multidrug resistance by an anti-CD19 ab.$245,700
R01 · FY2005 · CA
IMMUNOTOXIN-DEPLETION OF HIV-1+ T CELLS$94,156
P51 · FY2005 · RR
Immunotoxin-Induced Vascular Leak Syndrome$73,320
R01 · FY2005 · CA
A Novel Recombinant Protein Vaccine Against Ricin Toxin$701,754
U01 · FY2004 · AI
The reversal of multidrug resistance by an anti-CD19 ab.$245,700
R01 · FY2004 · CA
Immunotoxin-Induced Vascular Leak Syndrome$73,320
R01 · FY2004 · CA
IMMUNOTOXIN-DEPLETION OF HIV-1+ T CELLS$52,670
P51 · FY2004 · RR
A Novel Recombinant Protein Vaccine Against Ricin Toxin$635,940
U01 · FY2003 · AI
Immunotoxin-Induced Vascular Leak Syndrome$337,122
R01 · FY2003 · CA
IMMUNOTOXIN-DEPLETION OF HIV-1+T CELLS$312,948
R01 · FY2003 · AI
IMMUNOTOXIN-DEPLETION OF HIV-1+T CELLS$312,948
R01 · FY2002 · AI
IMMUNOTOXIN INDUCED VASCULAR LEAK SYNDROME$283,237
R01 · FY2002 · CA
IMMUNOTOXIN-DEPLETION OF HIV-1+T CELLS$326,948
R01 · FY2001 · AI
IMMUNOTOXIN INDUCED VASCULAR LEAK SYNDROME$274,987
R01 · FY2001 · CA
SIGNALING AND ANTITUMOR EFFECTS OF ANTIBODIES$222,883
R01 · FY2001 · CA
IMMUNOTOXIN INDUCED VASCULAR LEAK SYNDROME$61,901
R01 · FY2001 · CA
IMMUNOTOXIN INDUCED VASCULAR LEAK SYNDROME$266,975
R01 · FY2000 · CA
SIGNALING AND ANTITUMOR EFFECTS OF ANTIBODIES$216,388
R01 · FY2000 · CA
IMMUNOTOXIN INDUCED VASCULAR LEAK SYNDROME$61,901
R01 · FY2000 · CA